Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

KEYNOTE-598 Investigators

Research output: Contribution to journal › Article › peer-review

142 Scopus citations

Fingerprint

Dive into the research topics of 'Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences